Abstract
The immunogenicity of recombinant human erythropoietin (r-HuEpo) by subcutaneous exposure has been well described. This adverse immunological effect causes anti-r-HuEpo-associated pure red cell aplasia (PRCA). There have been increasing cases of anti-r-HuEpo-associated PRCA after subcutaneous exposure in Thailand. The casual mechanism of this disease may relate to HLA immunogenic, protein aggregation, stability during storage and handling of drug products, formulation and drug product quality.
The r-HuEpos have been licensed for treatment of renal anemia in Thailand include innovator products and more than 20 biosimilar products. Lack of a scientific product characterization and quality driven process to approve such biosimilars may lead to different immunogenicity and safety profiles. The Prospective Immunogenicity Surveillance Registry of r-HuEpo with Subcutaneous Exposure in Thailand estimated the incidence of anti-r-HuEpo associated PRCA among subjects who had subcutaneous exposure to any r-HuEpo product currently available in Thailand, addressed the risk of anti-r-HuEpo-associated PRCA, and the association of product qualities towards adverse immunogenicity.
The experiences of biosimilar r-HuEpo in Thailand and anti-rHuEpo associated PRCA in Thailand illustrated the need to evaluate biosimilar product on a case-by case basis. Considering patients ‘safety as the first priority, the approval process for biosimilar drug licensing should be designed to assess quality, characterization and impurity profile and comprehensive evaluation of the non-clinical and clinical aspects. Pharmacovigilance could be the final step to narrow the gap between quality and safety and can be assessed in totality with cost-effectiveness and patient benefit that such drug offer.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bennett CL, Luminari S, Nissenson AR, etal. Pure red-cell aplasia and epoetin therapy. New Engl J Med. 2004;351:1403–8.
Blackstone E, Fuhr J. The economics of biosimilars. Am Health Drug Benefits. 2013;6(8):469–78.
Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, Power D, Rossert J, Casadevall N. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67(6):2346–53.
Bracewell DG, Francis R, Smales CM. The future of host cell protein (HCP) identification during process development and manufacturing linked to a risk-based management for their control. Biotechnol Bioeng. 2015;112:1727–37.
Casadevall N. Antibodies against r-HuEPO: native or recombinant. Nephrol Dial Transplant. 2002;17(Suppl 5):42–7.
Casadevall N, Nataf J, Viron B, etal. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. New Engl J Med. 2002;346:469–75.
Casadevall N, Thorpe R, Schellekens H. Biosimilars need comparative clinical data. Kidney Int. 2011;80:553.
Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22(11):1383–91.
Combe C, Tredree RL, Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy. 2005;25:954–62.
Deechongkit S, Aoki KH, Park SS, Kerwin BA. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen® and Eprex®. J Pharm Sci. 2006;95:1931–43.
Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv. 2009;27:297–306.
Dorey E. How the biologics landscape is evolving. Clin Pharm. 2014;6(9):1–6.
Dzieciatkowska M, Hill R, Hansen KC. GeLC-MS/MS analysis of complex protein mixtures. Methods Mol Biol. 2014;1156:53–66.
Erslev AJ. Pure red cell aplasia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill; 1995. p. 448.
FDA Briefing Document. Onchologic Drugs Advisory Committee Meeting, May 25, 2017, BLA 125545 “Epoetin Hospira”, a proposed biosimilar to Epogen/Procrit 9epoetin alfa). Applicant: Hospira Inc., Pfizer Company.
Fijal B, Ricci D, Vercammen E, Palmer PA, Fotiou F, Fife D, Lindholm A, Broderick E, Francke S, Wu X, Colaianne J, Cohen N. Case-control study of the association between select HLA genes and anti-erythropoietin antibody-positive pure red-cell aplasia. Pharmacogenomics. 2008;9(2):157–67.
Fujimori K, Lee H, Phillips J, Nashed-Samuel Y. Development of an inductively coupled plasma mass spectrometry method for quantification of extracted tungsten from glass prefilled syringes used as a primary packaging for pharmaceutical and therapeutic protein products. PDA J Pharm Sci Technol. 2013;67(6):670–9.
Haag-Weber M, Eckardt KU, Hörl WH, Roger SD, Vetter A, Roth K. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Clin Nephrol. 2012;77(1):8–17.
Halim LA, Brinks V, Jiskoot W, Romeijn S, Praditpornsilpa K, Assawamakin A, Schellekens H. How bio-questionable are the different recombinant human erythropoietin copy products in Thailand? Pharm Res. 2014;31(5):1210–8.
Heavner GA, Arakawa T, Philo JS, Calmann MA, LaBrenz S. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: follow-up to “a case study using Epoetin Alfa from Epogen and EPREX”. J Pharm Sci. 2007;96:3214–25.
Hung S, Chung W, Liou L, etal. HLA-B * 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134–9.
Jenke D. Extractable/leachable substances from plastic materials used as pharmaceutical product containers/devices. PDA J Pharm Sci Technol. 2002;56:332–71.
Joung J, Robertson JS, Griffiths E, WHO Informal Consultation Group, etal. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19–20 April 2007. Biologicals. 2008;36:269–76.
Lacombe C. Resistance to erythropoietin. New Engl J Med. 1996;334:660–2.
Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia ‘epidemic’– mystery completely revealed? Perit Dial Int. 2007;27(Suppl 2):S303–7.
Macdougall IC, Roger SD, de Francisco A, etal. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727–32.
Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di Paolo S, Kribben A, Fliser D, Messner H, McNeil J, Stevens P, Santoro A, De Francisco ALM, Percheson P, Potamianou A, Foucher A, Fife D, Mérit V, Vercammen E, PRIMS Study Group. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the prospective immunogenicity surveillance registry (PRIMS). Nephrol Dial Transplant. 2015;30(3):451–60.
Mallal S, Nolan C, Witt C, etal. Association between presence of HLA-B * 5701, HLA-DR-7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–32.
Mandreoli M, Finelli C, Lopez A, Ascani S, Vianelli N, Baccarani M, Santoro A. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis. 2004;44(4):757–61.
Matsuhashi N, Yoshioka T. Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients. Nephron. 2002;92:601–4.
McLeod D, Shreeve M, Axeirad A. Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E. Blood. 1974;44:517–34.
Moussa EM, etal. Immunogenicity of therapeutic protein aggregates. J Pharm Sci. 2016;105: 417–30.
Park SS, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, Wong W, Kerwin BA. Biochemical assessment of erythropoietin products from Asia versus US Epoetin Alfa manufactured by Amgen. J Pharm Sci. 2009;98:1688–99.
Peces R, Torre M, Alcazar R, Urra J. Antibodies against recombinant human erythropoietin in a patient with erythropoietin resistance anemia. New Engl J Med. 1996;3356:523–4.
Porter S. Human immune response to recombinant human proteins. J Pharm Sci. 2001;90:1–11.
Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol. 1997;47:331–5.
Praditpornsilpa K, Buranasot S, Bhokaisuwan N, Avihingsanon Y, Pisitkul T, Kansanabuch T, Eiam-Ong S, Chusil S, Intarakumtornchai T, Tungsanga K. Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation. Nephrol Dial Transplant. 2005;20(3):626–30.
Praditpornsilpa K, Kupatawintu P, Mongkonsritagoon W, Supasyndh O, Jootar S, Intarakumthornchai T, Pongskul C, Prasithsirikul W, Achavanuntakul B, Ruangkarnchanasetr P, Laohavinij S, Eiam-Ong S. The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1∗09-DQB1∗0309. Nephrol Dial Transplant. 2009;24:1545–9.
Praditpornsilpa K, Tiranathanagul K, Kupatawintu P, Jootar S, Intragumtornchai T, Tungsanga K, Teerapornlertratt T, Lumlertkul D, Townamchai N, Susantitaphong P, Katavetin P, Kanjanabuch T, Avihingsanon Y, Eiam-Ong S. Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies. Kidney Int. 2011;80(1):88–92.
Praditpornsilpa K, Tiranathanakul K, Jootar S, Tungsanga K, Eiam-Ong S. Rechallenge with intravenous recombinant human erythropoietin can be successful following the treatment of anti-recombinant erythropoietin associated pure red cell aplasia. Clin Nephrol. 2014;81(5):355–8.
Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005;5(8):617–28.
Ryan MH, Heavner GA, Brigham-Burke M, etal. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. Int Immunopharmacol. 2006;6:647–55.
Sahoo N, Choudhury K, Manchikanti P. Manufacturing of biodrugs: need for harmonization in regulatory standards. BioDrugs. 2009;23(4):217–29.
Schellekens H. When biotech proteins go off-patent. Trends Biotechnol. 2004;22:406–41.
Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced denaturation and aggregation of epoetin Alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.
Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126(2):114–8.
Solá RJ, Griebenow K. Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci. 2009;98:1223–45.
Thanaphollert P, Tungsanga K. Towards regulation of similar biotherapeutic products: Thailand’s perspective. Biologicals. 2011;39:346–7.
Treerutkuarkul A. Thailand: health care for all, at a price. Bull World Health Organ. 2010;88(2):84–5.
Urra J, Torre M, Alcaza P, Peces R. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clin Chem. 1997;43: 848–9.
Walsh G. Biopharmaceutical benchmarks 2014. Nat Biotechnol. 2014;32(10):992–1000.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Praditpornsilpa, K., Assawamakin, A., Tungsanga, K. (2018). Immunogenicity and Adverse Reactions to Biosimilar Erythropoietin Products in Thailand: The Significance of Science and Quality Driven Process for Approval. In: Gutka, H., Yang, H., Kakar, S. (eds) Biosimilars. AAPS Advances in the Pharmaceutical Sciences Series, vol 34. Springer, Cham. https://doi.org/10.1007/978-3-319-99680-6_25
Download citation
DOI: https://doi.org/10.1007/978-3-319-99680-6_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-99679-0
Online ISBN: 978-3-319-99680-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)